Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Int J Cancer. 2018 Sep 19;143(10):2470–2478. doi: 10.1002/ijc.31756

Figure 1: Triptolide inhibits tumorigenicity and metastasis.

Figure 1:

a) Spontaneous tumor incidence in E160D FEN1 mutant mice with or without subcutaneous triptolide treatment, n=20 for each group. The tumor incidence in each group was determined by anatomical analysis and histopathology. P-values were calculated using the Fisher Exact test. b) Colony formation assays of A549 lung cancer cells cultured in the indicated concentrations of triptolide. c) Representative tumor formation in NSG Xenograft mice untreated or treated subcutaneously with triptolide, n = 6 for each group. d) Haematoxylin and Eosin (H&E) staining of tumor or lung tissue after 8 weeks of subcutaneous triptolide treatment, n=6 for each group. Black arrows indicate metastatic nodules. e) A549 cells untreated or treated with 10 nM triptolide for 48h, then analyzed over FACS using a fluorescent annexin assay. f) A549 cells were treated with the indicated concentrations of triptolide for 48 h, stained with PI and analyzed by FACS. The proportion of DNA in the S-phase was calculated using ModfitLT Version 3.0 Software. Data are shown as the mean ± SD (error bars) from three independent experiments.